All In Biotech

Drug Trial Radar · NCT05419388

A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Aug 15, 2022

Primary completion

May 1, 2024

Study completion Nov 27, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of two dose levels of RO7247669 in participants with unresectable or metastatic melanoma to select the recommended dose for further development.

Conditions

  • Melanoma

Interventions

  • RO7247669Drug

    Participants will receive intravenous (IV) RO7247669 Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From randomization to the first occurrence of progression or death during the treatment period or within 60 days of the last tumor assessment after treatment discontinuation from any cause, whichever occurs first (up to 25 months)

Locations

22 sites in 10 countries. Site status is shown where the registry gives one.

  • Coffs Harbour Health Campus

    Coffs Harbour, New South Wales, Australia

  • Melanoma Institute Australia

    North Sydney, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • One Clinical Research

    Nedlands, Western Australia, Australia

  • Hospital de Clínicas de Porto Alegre X

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • Hospital Sírio-Libanês

    São Paulo, São Paulo, Brazil

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Všeobecná fakultní nemocnice v Praze

    Prague, Czechia

  • District General Hospital of Athens Laiko

    Athens, Greece

  • Auckland City Hospital, Cancer and Blood Research

    Auckland, New Zealand

  • Wellington Hospital

    Wellington, New Zealand

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, Poland

  • Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie

    Warsaw, Poland

  • Narodny Onkologicky Ustav

    Bratislava, Slovakia

  • POKO Poprad

    Poprad, Slovakia

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Clínic i Provincial

    Barcelona, Spain

  • Adana Baskent University Hospital

    Adana, Turkey (Türkiye)

  • Memorial Ankara Hastanesi

    Ankara, Turkey (Türkiye)

  • Medipol Mega Üniversite Hastanesi Göztepe

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.